Domestic AI-Driven Biotech Moves Second In-House Drug into Clinical Development

　　【Pharmaceutical Network Enterprise NewsRecently, MindRank's self-developed WEE1/YES1 dual inhibitor MRANK-106 has received FDA clinical approval in the United States and will commence clinical research targeting various solid tumors. MRANK-106 is an orally administered WEE1/YES1 dual kinase inhibitor. Designed with AI assistance, the drug demonstrates high tissue/tumor targeting specificity and has shown significant efficacy against multiple cancers in preclinical studies.
 

MindRank is a clinical-stage AI-driven innovative drug discovery company committed to continuously delivering differentiated and high-clinical-value drug candidates by promoting the integration of various cutting-edge technologies in artificial intelligence and new drug development, thereby helping more lives regain health.
 

MRANK-106 is the second potential self-developed drug by the company to enter clinical stage within three years, and also the company's first First-in-Class candidate drug to enter clinical trials. This approval signifies that its new drug development, supported by rigorously validated multi-million high-quality datasets and top-tier self-developed large-scale artificial intelligence algorithms, has achieved a certain level of precision and reliability.
 

According to reports, MindRank's first self-developed GLP-1RA small molecule oral drug MDR-001 has completed the first dosing group in Phase IIb clinical trials. Clinical research results show that MDR-001 demonstrates good safety and pharmacokinetic characteristics, with a clear linear relationship across different dose groups, and its preclinical advantages have been successfully translated into clinical settings. Notably, with the help of its self-developed one-stop AI drug discovery platform Molecule Pro, the MDR-001 project took only 19 months from initiation to obtaining the IND approval.
 

The process of drug development has always been long and arduous. The fact that MindRank has managed to bring two self-developed drugs into clinical trials within three years demonstrates the significant role AI technology is playing in the pharmaceutical field. In fact, in order to reduce costs, improve efficiency, quickly identify potential targets, and shorten the clinical trial cycle, AI technology has rapidly permeated all aspects of research and development in recent years, and the AI pharmaceuticals market has begun to show vigorous growth.
 

Currently, in China, like MindRank, there are already many companies leveraging AI to accelerate new drug development. These include startups specializing in AI-driven drug discovery such as XtalPi and Insilico Medicine, as well as traditional pharmaceutical companies like Hengrui Medicine and CSPC Pharmaceutical Group, which are actively embracing AI technology through strategic cooperation and equity investment to expedite the innovation of new drugs.
 

Statistics show that, as of January 2024, more than 10 AI drug discovery companies in China have advanced pipelines into clinical stages, with the number of AI drug discovery pipelines entering clinical stages reaching 34. Among them, self-developed is the primary R&D model, accounting for 85%. Additionally, as of December 16, 2024, there were a total of 35 strategic cooperation and pipeline transactions related to AI pharmaceuticals globally in 2024, of which 12 transactions were related to Chinese companies.
 

Overall, AI-driven drug discovery in the Chinese market is in a period of rapid growth with immense potential, and it is expected to further accelerate the transformation and upgrading of the entire pharmaceutical industry in the future.
 

　Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.